Action VKTX VIKING THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Viking Therapeutics, Inc.

Actions

VKTX

US92686J1060

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
74,31 USD +7,91 % Graphique intraday de Viking Therapeutics, Inc. +17,17 % +299,30 %
24/04 Viking Therapeutics aggrave sa perte au premier trimestre ; les actions chutent après les heures de bureau MT
24/04 Transcript : Viking Therapeutics, Inc., Q1 2024 Earnings Call, Apr 24, 2024

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours
Viking Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
6 Stocks Positioned to Soar as Investors Focus on MASH
Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup
Health Care Down on Flight From Risk -- Health Care Roundup
Health Care Down as Obesity-Drug Optimism Fades -- Health Care Roundup
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup
Sector Update: Health Care Stocks Rise Tuesday Afternoon
Sector Update: Health Care
Viking Therapeutics Share Rise After Reporting 'Positive Results' in Study of Potential Obesity Drug
Sector Update: Health Care Stocks Steady Premarket Tuesday
Sector Update: Health Care
Viking Therapeutics Reports 'Positive Results' in Study of Potential Obesity Drug; Shares Jump
PE firm Olympus to sell 9.8% stake in India's Aster DM Healthcare for up to $234.5 million, term sheet shows
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking Therapeutics Announces $632.5 Million Public Offering Of Common Stock
Viking Therapeutics Raises $632.5 Million Via Common Stock Offering
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action VKTX
  4. Actualités Viking Therapeutics, Inc.
  5. Autres langues